Evidence map›Paper›PMID 40523200›Full record

ArticleCancer immunology research2025

In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.

Colin Y C Lee, Isaac Dean, Nathan Richoz, Zhi Li, Bethany C Kennedy, Lisa A Vettore, Youhani Samarakoon, Kathryn L Gilroy, Tetsuo Hasegawa, Gianluca Carlesso and 7 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Association of intratumoral CD68Frontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Colin Y C LeeMolecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8380-4917
Isaac DeanInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-4750-5335
Nathan RichozMolecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7422-3237
Zhi LiInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-0583-1116
Bethany C KennedyInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0001-9529-7545
Lisa A VettoreInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0001-8396-5358
Youhani SamarakoonCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-9845-4232
Kathryn L GilroyCancer Research UK Scotland Institute, Glasgow, United Kingdom.ORCID 0000-0003-4607-194X
Tetsuo HasegawaMolecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-7737-9491
Gianluca CarlessoEarly Oncology R&D, AstraZeneca, Gaithersburg, Maryland.ORCID 0000-0002-9592-3267
Scott A HammondEarly Oncology R&D, AstraZeneca, Gaithersburg, Maryland.ORCID 0000-0001-5800-4328
Simon J DovediEarly Oncology R&D, AstraZeneca, Cambridge, United Kingdom.ORCID 0000-0003-0486-1206
Owen J SansomCancer Research UK Scotland Institute, Glasgow, United Kingdom.ORCID 0000-0001-9540-3010
Zewen K TuongMolecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-6735-6808
Timotheus Y F HalimCancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-9773-0023
David R WithersInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0003-3757-7594
Menna R ClatworthyMolecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-3340-9828

Funding

Cancer Research Institute (CRI) CRI3128Cancer Research UK 26825Cancer Research UK 27535Cancer Research UK (CRUK) ACRCelerate - A26825Cancer Research UK (CRUK) C54019/A27535Gates Cambridge TrustNIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC)Wellcome Trust 220268Wellcome Trust (WT) 220268/Z/20/ZWorld Cancer Research Fund (WCRF) 21-0073
6 · The paper itself

Abstract

Tumor-associated macrophages (TAM) are a universal feature of cancers but variably influence outcomes and treatment responses. In this study, we used a photoconvertible mouse to distinguish newly entering, monocyte-derived TAMs (mdTAM) that were enriched at the tumor core from resident-like TAMs that localized with fibroblasts at the tumor-normal interface. The mdTAM pool was highly dynamic and continually replenished by circulating monocytes. Upon tumor entry, these monocytes differentiated down two divergent fate trajectories distinguished by the expression of MHC class II. MHC-II+ mdTAMs were functionally distinct from MHC-II- mdTAMs, demonstrating increased capacity for endocytosis and Fc-gamma receptor-mediated phagocytosis, as well as proinflammatory cytokine production. Both mdTAM subsets showed reduced expression of inflammatory transcripts and increased expression of PD-L1 with increasing tumor dwell time. Treatment with anti-PD-L1 skewed mdTAM differentiation toward the MHC-II+ fate and attenuated the anti-inflammatory effects of the tumor environment. Anti-PD-L1 enhanced mdTAM-CD4+ T cell interactions, establishing an IFNγ-CXCL9/10-dependent positive feedback loop. Altogether, these data resolve distinct temporal, spatial, and functional properties of TAMs and provide evidence of subset-specific effects of PD-L1 blockade.

Indexed as

B7-H1 AntigenImmune Checkpoint InhibitorsTumor-Associated MacrophagesAnimalsCell DifferentiationHumansMacrophagesMiceMice, Inbred C57BLMonocytesTumor MicroenvironmentB7-H1 AntigenImmune Checkpoint Inhibitors

Identifiers

PMID40523200
PMCPMC7617970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.